Haleon PLC Reports Strong Profit Growth and Upgraded Guidance

Haleon PLC Sponsored ADR ( (HLN) ) has released its Q2 earnings. Here is a breakdown of the information Haleon PLC Sponsored ADR presented to its investors.

Haleon PLC, a global leader in consumer health, specializes in products across categories such as Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. The company’s portfolio includes well-known brands like Advil, Sensodyne, and Centrum, emphasizing innovation and consumer trust.

In its latest half-year earnings report for 2025, Haleon PLC reported strong organic operating profit growth, leading to an upgrade in its full-year profit guidance. The company experienced robust growth in the EMEA and Latin America regions, as well as in the Asia-Pacific market, despite a slight decline in North America due to a challenging consumer environment.

Key financial highlights include a 3.2% organic revenue growth, driven by a 2.4% increase in pricing and a 0.8% rise in volume/mix. The Oral Health segment outperformed with a 7.6% organic revenue growth. Haleon also reported a 9.9% increase in organic operating profit, with a 140 basis point improvement in operating profit margin. The company’s free cash flow reached £734 million, and it declared a 10% increase in its interim dividend.

Haleon continues to focus on strategic initiatives, including share buybacks and the acquisition of a remaining equity interest in its China OTC joint venture. The company expects organic revenue growth of around 3.5% for the full year, with high single-digit organic operating profit growth.

Looking ahead, Haleon remains optimistic about its growth prospects, driven by innovations and strategic investments across its global markets. The company is confident in its ability to deliver medium-term guidance and enhance shareholder returns through disciplined capital allocation.